VANCOUVER, BC / ACCESS Newswire / September 22, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") is pleased to announce the appointment of Dr. Michael Lock, Professor in the Department of Oncology and the Department of Medical Biophysics at the University of Western Ontario, to its Scientific and Clinical Advisory Board. Dr. Lock's expertise in clinical trial design, translational oncology, and multidisciplinary cancer care will support Onco i ...

公司运营重组 - 公司宣布重组运营以更好匹配战略重点 包括削减约34%的全球员工[1] - 重组预计带来约1360万美元的年化成本节约[1] - 此次裁员代表重组计划中所有预期的员工相关行动[4] 财务表现与展望 - 2025年核心收入预计与2024年持平或下降约10%[3] - 全年SPL项目相关收入预计约为500万美元[3] - 年底现金及现金等价物和投资预计至少为1.55亿美元[3] 战略方向 - 重组旨在显著降低运营支出 简化组织结构并加速实现盈利[2] - 资源重新调整是推动高效增长和实现盈利规模化的更广泛战略举措[4] - 公司正在建立持续改进的文化 并预期有非员工相关的机会改善盈利状况[4] 业务描述 - 公司是领先的细胞工程平台技术提供商 专注于推动下一代细胞疗法的发现、开发和商业化[5] - 核心技术包括Flow Electroporation®技术和SeQure DX™基因编辑风险评估服务[5] - 拥有超过25年细胞工程经验 为全球研究人员提供科学、技术和监管指导[5]

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Jasper Therapeutics, Inc. ("Jasper†or the "Company†) (NASDAQ: JSPR) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON JASPER THERAPEUTICS, INC. (JSPR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On July 7, 2025, Jasper released an update on its Phas. ...

VICTORIA, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, is pleased to announce the Company has filed a preliminary prospectus supplement (the “Supplement”) to its short form base shelf prospectus dated February 5, 2024 (the “Base ...

SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Jasper Therapeutics, Inc. (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025. Jasper, a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (“CSU”), Chronic Inducible Urticaria (“CIndU”), and Asthma. For more informatio ...

NEW YORK--(BUSINESS WIRE)---- $JSPR #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Jasper Therapeutics, Inc. ("Jasper†or the "Company†) (NASDAQ: JSPR) and reminds investors of the November 18, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgi ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .It feels like I have spent a good portion of my adult life trying to keep friends and family from stepping on landmines, most of which seem obvious to me.Bret leads the investing group The Biotech Forum , in which he and his team offer ...

NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025, inclusive (the “Class Period”). The Complaint alleges that Defendants made false and/or misleading state ...

Alector (NasdaqGS:ALEC) Update / Briefing September 22, 2025 12:00 PM ET Company ParticipantsKatie Hogan - Senior Director - Corporate Communication & IRSara Kenkare-Mitra - President & Head - Research & DevelopmentArnon Rosenthal - Co-Founder, CEO & DirectorPete Stavropoulos - Director - Biotech Equity ResearchGiacomo Salvadore - Chief Medical OfficerJulian Pino - Senior Associate - Biotechnology Equity ResearchAlec Stranahan - VP - Equity ResearchGraig Suvannavejh - Managing DirectorConference Call Partic ...

ATLANTA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding Jasper’s business, operations, and compliance policies, including allegations that: (i) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on ...